A pause in HIV treatment for people with a strong immune profile
This trial tests whether you can safely stop your HIV medication for a while if your immune system has specific markers that might help control the virus. The goal is to see if a treatment pause could be an option for people like you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been on HIV medication for at least 2 years.
- Your viral load has been undetectable and your CD4 count is 500 or higher at the start.
- You have certain immune system markers (a specific genetic type and a high number of natural killer cells).
- You have not had a low CD4 count below 200 (if you were diagnosed during early infection) or below 350 (if diagnosed later).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study uses special scans (PET/CT) and tissue sampling (biopsy) to learn what is happening in the body while people with HIV take a planned break from antiretroviral therapy (ART) for up to 90 days. It may help researchers find better ways to control HIV without ongoing treatment, though joining involves careful monitoring during the pause.
This trial tests whether a combination of powerful antibodies (bNAbs) can help control HIV after stopping standard HIV treatment. Participants will pause their daily HIV medications while receiving these antibodies, and doctors will closely monitor their immune system and virus levels. It's for people who are already well-controlled on HIV treatment and have participated in a specific earlier study.
This study looks at whether some people with HIV can keep the virus controlled even if they temporarily stop HIV medicines (an “analytic treatment interruption”). If you qualify, it may help researchers learn what it would take for an HIV cure.
This study looks at what happens when HIV treatment (ART) is intentionally paused in people who are already enrolled in a specific research study (RV254) and recently joined a protocol that included an earlier treatment pause. It may help researchers understand safety and how to manage treatment changes, but it has strict participation and consent requirements.
This study tests whether giving a small protein called IL-15 can help your immune system keep HIV under control after pausing your daily HIV medications. You will stop your meds for a short time under careful monitoring, and the hope is that your body might learn to fight HIV without daily pills.
This Phase 1 trial tests two new HIV vaccines (DV700P-RNA and DV701B1.1-RNA) combined with a monitored break from HIV medications in people with well-controlled HIV. The goal is to see if this approach safely strengthens the immune system's ability to fight HIV.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.